Tadalafil and Steroid Hormones Interactions in Adipose, Bone and Prostate Tissues: Focus on Translational Perspectives.

Emanuela Alessandra Greco, Cristina Antinozzi, Luigi Di Luigi, Antonio Aversa, Paolo Sgrò

Open access · goldAbstract readReview

In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.4field-weighted citation impact, top 37% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Emanuela Alessandra GrecoDepartment Unicusano, University "Niccolò Cusano", 00166 Rome, Italy.

Cristina AntinozziDepartment of Movement, Human and Health Sciences, "Foro Italico" University, 00135 Rome, Italy.ORCID 0000-0003-4296-5081

Luigi Di LuigiDepartment of Movement, Human and Health Sciences, "Foro Italico" University, 00135 Rome, Italy.ORCID 0000-0002-2522-126X

Antonio AversaDepartment of Experimental and Clinical Medicine, Magna Græcia University, 88100 Catanzaro, Italy.ORCID 0000-0002-2989-2618

Paolo SgròDepartment of Movement, Human and Health Sciences, "Foro Italico" University, 00135 Rome, Italy.ORCID 0000-0003-4929-2764

Foro Italico University of Rome · ITMagna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tadalafil is a selective phosphodiesterase type-5 (PDE5) inhibitor that is approved for the treatment of men with erectile dysfunction (ED) and/or benign prostate hyperplasia (BPH) -associated symptoms. Besides its classical actions on PDE5 within the genitourinary tract, where the specific enzyme expression is maximal, it may exert different systemic effects. This is mainly due to the pleiotropic distribution of PDE5 enzyme throughout the human (and animal) body, where it can exert protective effects in different clinical conditions. Recently, it has been demonstrated that tadalafil may display novel actions on androgen receptor (AR) expression and activity and cytochrome P19a1 (Cyp19a1) and estrogen receptor β (ERβ) expression in different in vitro systems, such as adipose, bone and prostate cancer cells, where it can act as a selective modulator of steroid hormone production. This may determine novel potential mechanism(s) of control in pathophysiologic pathways. In this review, we summarize basic research and translational results applicable to the use of tadalafil in the treatment of obesity, bone loss and prostate cancer.

Indexed as

Erectile DysfunctionProstatic HyperplasiaProstatic NeoplasmsAnimalsCarbolinesCyclic Nucleotide Phosphodiesterases, Type 5HormonesHumansMalePhosphodiesterase 5 InhibitorsProstateSteroidsTadalafilTreatment OutcomeCarbolinesCyclic Nucleotide Phosphodiesterases, Type 5HormonesPhosphodiesterase 5 InhibitorsSteroidsTadalafiladipocytesandrogen receptorsaromataseboneobesityosteoporosisprostate cancertadalafil

Identifiers

PMID35457011

DOI10.3390/ijms23084191

PMCPMC9024809

OpenAlexW4223442020

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.